Author response to Braillon: Practice guideline update summary: Mild cognitive impairment: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology
Ronald C.Petersen, Neurologist, Mayo Clinic
OscarLopez, Neurologist, University of Pittsburgh Medical Center
Melissa J.Armstrong, Neurologist, University of Florida College of Medicine
Thomas S.D.Getchius, Manager, Heart Rhythm Society
MaryGanguli, Psychiatrist, Department of Psychiatry, University of Pittsburgh
DavidGloss, Neurologist, Charleston Area Medical Center Neurology
Gary S.Gronseth, Neurologist, University of Kansas Medical Center
DanielMarson, Clinical Neuropsychologist, University of Alabama at Birmingham
TamaraPringsheim, Neurologist, Cumming School of Medicine, University of Calgary
Gregory S.Day, Neurologist, Knight Alzheimer Disease Research Center, Washington University School of Medicine
MarkSager, Geriatrician, School of Medicine and Public Health, University of Wisconsin
JamesStevens, Neurologist, Fort Wayne Neurological Center
Alexander D.Rae-Grant, Neurologist, Cleveland Clinic Neurological Institute at Lakewood Hospital
Submitted March 01, 2018
We thank Dr. Braillon for his thoughtful comments on our guideline. [1] We echo his concerns about the lack of awareness regarding MCI risk factors such as alcohol consumption and the lack of supporting evidence for use of pharmacologic agents for treating MCI, particularly anticholinergic medications. It is our hope that this guideline will play a key role in changing such misperceptions.
1. Petersen RC, Lopez O, Armstrong MJ et al. Practice guideline update summary: Mild cognitive impairment: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018;90:126-135.
We thank Dr. Braillon for his thoughtful comments on our guideline. [1] We echo his concerns about the lack of awareness regarding MCI risk factors such as alcohol consumption and the lack of supporting evidence for use of pharmacologic agents for treating MCI, particularly anticholinergic medications. It is our hope that this guideline will play a key role in changing such misperceptions.
1. Petersen RC, Lopez O, Armstrong MJ et al. Practice guideline update summary: Mild cognitive impairment: Report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology 2018;90:126-135.